Chemomab Therapeutics Azioni (NASDAQ: CMMB)

Ultime notizie per Chemomab Therapeutics (NASDAQ:CMMB) Azioni

Chemomab Therapeutics

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics Ltd

WIIM

Analog Devices shares are trading higher after the company reported better-than-expected Q4 financial results.

Northland Capital Markets analyst Gus Richard maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Outperform and raises the price target from $46 to $60.

News

Price Target

Analyst Ratings

SMTC

Northland Capital Markets Maintains Outperform on Semtech, Raises Price Target to $60

AMGN

Amgen shares are trading lower following the results of its Phase 2 study with MariTide in obesity.

Kohl's shares are trading lower after the company reported worse-than-expected Q3 EPS and sales, cut its FY24 EPS guidance, and projected a net sales decrease of 7%-8%.

Keybanc analyst Jason Celino maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Overweight and raises the price target from $62 to $74.

GTLB

Keybanc Maintains Overweight on GitLab, Raises Price Target to $74

Novo Nordisk and Eli Lilly shares are trading higher after the Biden-Harris administration proposed a new step to expand coverage of anti-obesity medications for Medicare and Medicaid beneficiaries.

Guidance

Canopy Growth Board Reaffirms Confidence In Company's Strategic Direction

LDTC

LeddarTech Achieves ISO/IEC 27001 Certification, Strengthening Cybersecurity Framework

Keybanc analyst Justin Patterson maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Overweight and raises the price target from $38 to $55.

GLBE

Keybanc Maintains Overweight on Global E Online, Raises Price Target to $55

Wells Fargo initiates coverage on Thomson Reuters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NYSE">TRI</a>) with a Equal-Weight rating and announces Price Target of $165.

Initiation

Wells Fargo Initiates Coverage On Thomson Reuters with Equal-Weight Rating, Announces Price Target of $165

AVXL

Anavex Life Sciences Submits Blarcamesine Marketing Authorization Application To EMA For Alzheimer's Disease Treatment Approval

Management

Canopy Growth Names Current Board Member Luc Mongeau As Its Next CEO, Effective January 6, 2025

SL Green Realty Enters Contract To Purchase 500 Park Avenue For $130M

DCGO

DocGo Secures Two-Year Contract With Major Texas Health System For Medical Transportation Services

The FDA will review the updated sBLA within four months of submission. Theratechnologies therefore expects a decision around the end of March 2025. The new formulation is patent protected in the U.S. until 2033.

THTX

Theratechnologies Resubmits Supplemental Biologics License Application To FDA For F8 Formulation Of Tesamorelin

Abercrombie & Fitch Increases Full Year Outlook To Net Sales Growth Outlook From 12% - 13% To 14% -15%; Sees Q4 Net Sales To Grow 5% - 7%

Guggenheim analyst Robert Drbul upgrades Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) from Neutral to Buy and announces $30 price target.

Upgrades

CPRI

Guggenheim Upgrades Capri Holdings to Buy, Announces $30 Price Target

Wells Fargo analyst Matthew Akers upgrades Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) from Equal-Weight to Overweight and lowers the price target from $157 to $147.

SAIC

Wells Fargo Upgrades Science Applications Intl to Overweight, Lowers Price Target to $147

CGTX

Cognition Therapeutics Announces Completion of Final Visits In Phase 2 SHIMMER Study Of CT1812 For Dementia With Lewy Bodies

In his new role, Ball will serve on the company's executive leadership team and continue to report to Scott Lipesky, Executive Vice President and Chief Operating Officer.
Lipesky, who served as the company's CFO since 2017, was promoted to COO in May 2023, and will remain in that role, leading the company's global operations and growth strategies, while driving financial discipline, capital allocation and efficiency.
&nbsp;

Abercrombie & Fitch Names Robert Ball As CFO, Effective November 20, 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics reported promising results from its Phase 2 SPRING trial for CM-101, a p...

Chemomab's Positive Trial Results Boost Investor Confidence

Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.05

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Roth MKM analyst Jason Wittes maintained a Buy rating on Chemomab Therapeutics (CMMB – Research Report) today and set a price target of $9.00. The ...

Roth MKM Sticks to Their Buy Rating for Chemomab Therapeutics (CMMB)

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating today. Michael Okunewitch has given h...

Chemomab Therapeutics: Promising Clinical Progress and Strategic Regulatory Pathways Support Buy Rating

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics has announced that its shareholders approved a proposal to grant 126,848...

Chemomab Therapeutics Aligns Leadership Incentives with Shareholders

Chemomab Therapeutics (CMMB) announced that data from its Phase 2 SPRING trial in patients with primary sclerosing cholangitis was presented at the...

Chemomab highlights clincial activity of CM-101 at The Liver Meeting 2024

CMMB

Health Care

Markets

Press Releases

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Financing

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Earnings

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Present at September 2024 Investor Conferences

Chemomab Therapeutics to Present at October 2024 Investor Conferences

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

General

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Comments

Chemomab Therapeutics

Notizie

Ultime notizie per Chemomab Therapeutics (NASDAQ:CMMB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO